source
- CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potentialCSL will co-develop and co-promote Alentis Therapeutics' anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune diseas…
- 2026 Nobel Prize awarded to U.S. and German scientists for optogenetics breakthroughsThe 2026 Nobel Prize in Physiology or Medicine was awarded to three researchers for their pioneering work on optogenetics. The laureates-Karl Deisseroth of Stanford University and the Howard Hughe…